

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2617)**

**VOLUNTARY ANNOUNCEMENT**

**TransThera Sciences (Nanjing) Publishes Clinical Results of Tinengotinib as Monotherapy and in Combination with Atezolizumab for Advanced Solid Tumors on Nature Communications**

This announcement is made by TransThera Sciences (Nanjing), Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The Company announced the publication of clinical results of tinengotinib as monotherapy and in combination with atezolizumab for the treatment of advanced solid tumors have been published on Nature Communications (Impact Factor = 15.7).

Tinengotinib is a spectrum-selective multi-kinase inhibitor targeting FGFR1-3, JAK1/2, VEGFRs, and Aurora A/B kinases. This phase Ib/II conducted in China (NCT05253053) evaluated tinengotinib as monotherapy (Arm A, n=53, in patients with advanced solid tumors) and in combination with atezolizumab (Arm B, n=31, in patients with advanced biliary tract cancer).

Tinengotinib demonstrated antitumor activity both as monotherapy (objective response rate ORR: 16.7% in Arm A) and combined with atezolizumab (ORR: 22.6% in Arm B). In predefined exploratory subgroup analysis, notable efficacy was observed in cholangiocarcinoma (ORR: 30.8% in Arm A n=13; 25.0% in Arm B n=28). Tinengotinib monotherapy achieved favorable response in cholangiocarcinoma harboring FGFR2 fusion progressing on prior FGFR inhibitors (ORR: 66.7%). In patients with cholangiocarcinoma previously treated with immune checkpoint inhibitors (n=20), the combination regimen achieved an ORR of 20.0% and a disease control rate of 75.0%. These findings support further development of tinengotinib, both as monotherapy and in combination with immunotherapy.

**Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.**

By order of the Board  
**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**  
**Dr. Frank Wu**  
*Chairman and Chief Executive Officer*

Hong Kong, 17 May, 2026

*As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.*